Literature DB >> 14631548

Shear stress and von Willebrand factor in health and disease.

Han-Mou Tsai1.   

Abstract

Blood flow in the circulation creates shear stress that affects cell functions and cell-cell interactions. Recent studies reveal that shear stress is also critical in the homeostasis of the plasma glycoprotein von Willebrand factor (vWF). Because of its large molecular size, vWF has a flexible conformation that is uniquely responsive to shear stress. Exposure to shear stress causes conformational unfolding of vWF, enhancing its susceptibility to cleavage by a plasma zinc metalloprotease (a disintegrin and metalloprotease with thrombospondin type 1 motif [ADAMTS13]). In the absence of ADAMTS13, shear stress increases the capacity of vWF to support platelet aggregation. In normal individuals, a balance between endothelial secretion of an ultralarge form of vWF and intravascular proteolysis determines the size distribution of vWF multimers that seems to be optimum for hemostasis without imposing the risk of unwarranted platelet aggregation. In type 2A (group 2) von Willebrand disease, the mutant vWF is excessively susceptible to cleavage by ADAMTS13, resulting in a decrease of large vWF multimers and bleeding diathesis. In patients with aortic stenosis or the hemolytic-uremic syndrome, abnormally high levels of shear stress across the stenotic valve or in the microcirculation inflicted with thrombosis may promote cleavage of vWF by ADAMTS13, contributing to the loss of large multimers commonly observed among these patients. Conversely, a deficiency in ADAMTS13 because of genetic mutations or autoimmune inhibitors causes vWF- and platelet-rich microvascular thrombosis characteristic of thrombotic thrombocytopenic purpura.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14631548     DOI: 10.1055/s-2003-44556

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  26 in total

1.  Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers.

Authors:  Svenja Lippok; Matthias Radtke; Tobias Obser; Lars Kleemeier; Reinhard Schneppenheim; Ulrich Budde; Roland R Netz; Joachim O Rädler
Journal:  Biophys J       Date:  2016-02-02       Impact factor: 4.033

2.  Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Cui Jian; Juan Xiao; Lingjie Gong; Christopher G Skipwith; Sheng-Yu Jin; Hau C Kwaan; X Long Zheng
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

Review 3.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

Review 4.  Laboratory testing for von Willebrand disease: toward a mechanism-based classification.

Authors:  Richard Torres; Yuri Fedoriw
Journal:  Clin Lab Med       Date:  2009-06       Impact factor: 1.935

5.  Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?

Authors:  Wenhua Zhou; Lingli Dong; David Ginsburg; Eric E Bouhassira; Han-Mou Tsai
Journal:  J Biol Chem       Date:  2005-10-03       Impact factor: 5.157

6.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

Review 7.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

8.  Contribution of ADAMTS13 to the better cell engraftment efficacy in mouse model of bone marrow transplantation.

Authors:  Hideto Matsui; Maiko Takeda; Kenji Soejima; Yasunori Matsunari; Shogo Kasuda; Shiro Ono; Kenji Nishio; Midori Shima; Fumiaki Banno; Toshiyuki Miyata; Mitsuhiko Sugimoto
Journal:  Haematologica       Date:  2014-06-27       Impact factor: 9.941

Review 9.  The kidney in thrombotic thrombocytopenic purpura.

Authors:  H-M Tsai
Journal:  Minerva Med       Date:  2007-12       Impact factor: 4.806

10.  Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor.

Authors:  Xiaohui Zhang; Kenneth Halvorsen; Cheng-Zhong Zhang; Wesley P Wong; Timothy A Springer
Journal:  Science       Date:  2009-06-05       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.